The window to influence the FDA's peptide decision is closing soon

[Nelson Vergel]

TAKE ACTION​

Your Voice Has a Place in This Process

The FDA's Pharmacy Compounding Advisory Committee meets July 23 – 24 to evaluate seven peptides for potential inclusion on the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-C, Emideltide (DSIP), Semax, and Epitalon.

The public comment period is now open. Submit by Thursday, July 9 to have your input provided directly to the Committee. The docket closes Wednesday, July 22, and late comments are not considered.

If you have clinical experience with any of these substances or perspective on what a regulated compounding pathway means for your patients, this is the moment to put it on the record.
A paragraph or two from a licensed provider carries real weight. Write from your own experience, patient access gaps, clinical context, what a regulated pathway changes in practice.

CLICK HERE TO COMMENT:

https://www.regulations.gov/commenton/FDA-2025-N-6895-0001

 

[Nelson Vergel]

Thread 'FDA Peptide Compounding Update (April 2026)- What Happens to BPC-157, TB-500, and Other Popular Peptides?'

Apr 24, 2026

By Nelson Vergel | Updated April 24, 2026 | 7 min read


If you've been using compounded peptides — or considering them — the FDA just made several moves that directly affect what's available and what's coming under review. The agency updated its official 503A bulk drug substances list on April 15, 2026, and the changes impact some of the most widely discussed peptides in the longevity and men's health community, including BPC-157, TB-500, Semax, Epitalon, and Melanotan II.
Here's what the update actually says, what it means for access, and what to watch for in the coming...

• Nelson Vergel
• Replies: 2
• Forum: General Peptide Use & Information